In episode 439, Mike and James invite Adrienne to take us through the impressively large amount of evidence for the PDE5 inhibitors for erectile dysfunction. We find that the NNTs are 2-3 for the not clearly defined endpoint of successful intercourse. There is a 20% absolute increase in adverse effects… Read More
In episode 438, Mike and James discuss 4 studies that likely could change what you are doing, or saying to your patients in your practice. Hip replacements – they last longer than you may think, Vitamin D – bigger isn’t better, actinic keratosis – 5-Flurouracil is best, and weight loss… Read More
In episode 457, James and Mike yet again invite Joey Ton to go through the evidence around reaching a target serum urate level in patients with gout. As with many arbitrary thresholds determined from observational studies (sometimes), or just made up, when you properly study if there is a benefit… Read More
In episode 437, Mike and James invite Joey Ton to help us work through all the evidence around Platelet-Rich Plasma (PRP) injections for tendinopathies. The best evidence for Achilles tendinopathy, lateral epicondylitis, and rotator cuff tendinopathy shows no difference in pain, function or return to sport when PRP is compared… Read More
In episode 436, Mike and James invite Samantha Moe to help us work through the recent evidence suggesting that hydrocholorothiazide is associated with squamous cell skin cancer. We go over all the numbers and talk about how we use cohort data to figure out if an association needs to influence… Read More
